Cytokinetics (CYTK) Short Interest Ratio & Short Volume → BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad) Free CYTK Stock Alerts $65.27 -0.01 (-0.02%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Cytokinetics Short Interest DataCurrent Short Volume14,040,000 sharesPrevious Short Volume13,230,000 sharesChange Vs. Previous Month+6.12%Dollar Volume Sold Short$954.72 millionShort Interest Ratio / Days to Cover6.9Last Record DateApril 15, 2024Outstanding Shares104,580,000 sharesFloat Size100,930,000 sharesShort Percent of Float13.91%Today's Trading Volume1,174,612 sharesAverage Trading Volume2,737,606 sharesToday's Volume Vs. Average43% Short Selling Cytokinetics ? Sign up to receive the latest short interest report for Cytokinetics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCYTK Short Interest Over TimeCYTK Days to Cover Over TimeCYTK Percentage of Float Shorted Over Time Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. Cytokinetics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202414,040,000 shares $954.72 million +6.1%13.9%6.9 $68.00 3/31/202413,230,000 shares $927.56 million -10.6%13.3%4.2 $70.11 3/15/202414,800,000 shares $964.81 million +1.9%14.9%3.7 $65.19 2/29/202414,530,000 shares $1.05 billion +5.1%14.6%3.9 $72.24 2/15/202413,830,000 shares $1.09 billion +1.8%14.6%3.9 $78.56 1/31/202413,580,000 shares $1.06 billion -1.2%14.5%3.9 $78.13 Get the Latest News and Ratings for CYTK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. 1/15/202413,750,000 shares $1.18 billion -8.8%14.7%3.9 $85.60 12/31/202315,080,000 shares $1.26 billion +2.9%16.1%5.1 $83.49 12/15/202314,660,000 shares $528.79 million +9.0%15.7%6.7 $36.07 11/30/202313,450,000 shares $450.31 million -1.8%14.4%8.9 $33.48 11/15/202313,690,000 shares $449.44 million -3.1%14.6%10.1 $32.83 10/31/202314,130,000 shares $492.57 million +2.8%15.4%11.6 $34.86 10/15/202313,750,000 shares $470.39 million +5.3%15.0%13 $34.21 9/30/202313,060,000 shares $384.75 million +4.1%14.2%14.2 $29.46 9/15/202312,550,000 shares $429.59 million +8.1%13.7%15.7 $34.23 8/31/202311,610,000 shares $405.65 million +15.1%13.0%14.2 $34.94 8/15/202310,090,000 shares $330.04 million No Change11.3%12.4 $32.71 7/31/202310,090,000 shares $336.50 million -0.1%11.2%12.1 $33.35 7/15/202310,100,000 shares $352.79 million +1.5%11.3%11.8 $34.93 6/30/20239,950,000 shares $324.57 million +7.9%11.1%11.3 $32.62 6/15/20239,220,000 shares $326.76 million -2.5%10.3%10.2 $35.44 5/31/20239,460,000 shares $356.55 million +0.2%10.5%10.4 $37.69 5/15/20239,440,000 shares $367.69 million No Change10.5%9.4 $38.95 10/31/202211,340,000 shares $495.10 million -8.8%N/A9.9 $43.66 10/15/202212,440,000 shares $571.62 million +2.7%N/A10 $45.95 9/30/202212,110,000 shares $586.73 million +3.8%N/A9.5 $48.45 9/15/202211,670,000 shares $636.13 million -2.9%N/A7.7 $54.51 8/31/202212,020,000 shares $636.58 million -5.7%N/A8.1 $52.96 8/15/202212,740,000 shares $647.57 million +8.7%N/A9.2 $50.83 7/31/202211,720,000 shares $496.11 million -0.8%N/A8.6 $42.33 7/15/202211,810,000 shares $478.31 million +37.8%N/A9.4 $40.50 6/30/20228,570,000 shares $336.72 million +0.5%16.6%7.3 $39.29 6/15/20228,530,000 shares $350.67 million -2.0%16.5%10 $41.11 5/31/20228,700,000 shares $347.13 million -2.6%N/A10.1 $39.90 5/15/20228,930,000 shares $375.15 million +11.5%N/A9.6 $42.01 4/30/20228,010,000 shares $319.36 million +1.0%N/A7.9 $39.87 4/15/20227,930,000 shares $313.71 million +5.7%N/A7.9 $39.56 3/31/20227,500,000 shares $276.08 million +3.7%N/A6.9 $36.81 3/15/20227,230,000 shares $245.39 million -13.1%N/A6.7 $33.94 2/28/20228,320,000 shares $293.86 million +1.2%N/A7.7 $35.32The Weight Loss Pill That Could Disrupt a $32 Billion Industry (Ad)A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> CYTK Short Interest - Frequently Asked Questions What is Cytokinetics' current short interest? Short interest is the volume of Cytokinetics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 14,040,000 shares of CYTK short. 13.91% of Cytokinetics' shares are currently sold short. Learn More on Cytokinetics' current short interest. What is a good short interest ratio for Cytokinetics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CYTK shares currently have a short interest ratio of 7.0. Learn More on Cytokinetics's short interest ratio. Which institutional investors are shorting Cytokinetics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cytokinetics: Concourse Financial Group Securities Inc., Nomura Holdings Inc., HAP Trading LLC, TIG Advisors LLC, ADAR1 Capital Management LLC, Point72 Asset Management L.P., Artia Global Partners LP, Balyasny Asset Management L.P., Nomura Holdings Inc., Harvest Management LLC, PEAK6 Investments LLC, Capstone Investment Advisors LLC, and UBS Group AG. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Cytokinetics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.91% of Cytokinetics' floating shares are currently sold short. Is Cytokinetics' short interest increasing or decreasing? Cytokinetics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 14,040,000 shares, an increase of 6.1% from the previous total of 13,230,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cytokinetics' float size? Cytokinetics currently has issued a total of 104,580,000 shares. Some of Cytokinetics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cytokinetics currently has a public float of 100,930,000 shares. How does Cytokinetics' short interest compare to its competitors? 13.91% of Cytokinetics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Cytokinetics: Elanco Animal Health Incorporated (3.14%), Ionis Pharmaceuticals, Inc. (7.12%), Intra-Cellular Therapies, Inc. (3.71%), Jazz Pharmaceuticals plc (6.14%), Blueprint Medicines Co. (6.94%), Apellis Pharmaceuticals, Inc. (8.80%), Cerevel Therapeutics Holdings, Inc. (9.10%), Legend Biotech Co. (6.04%), BridgeBio Pharma, Inc. (10.86%), Organon & Co. (4.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Cytokinetics stock? Short selling CYTK is an investing strategy that aims to generate trading profit from Cytokinetics as its price is falling. CYTK shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cytokinetics? A short squeeze for Cytokinetics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CYTK, which in turn drives the price of the stock up even further. How often is Cytokinetics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYTK, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ELAN Short Interest Data IONS Short Interest Data ITCI Short Interest Data JAZZ Short Interest Data BPMC Short Interest Data APLS Short Interest Data CERE Short Interest Data LEGN Short Interest Data BBIO Short Interest Data OGN Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CYTK) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarnings